Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Acting Chief Scientist Offers Vaccine Continuity As Goodman Departs

This article was originally published in The Pink Sheet Daily

Executive Summary

Jesse Goodman will become director of Georgetown University’s new Center on Medical Product Access, Safety and Stewardship while Stephen Ostroff steps up as FDA’s Acting Chief Scientist.

You may also be interested in...



CBER Director Midthun Retiring; Legacy Includes Biosimilar Principles, Avastin Withdrawal

While CBER is often perceived to be as much focused on research as it is on application review, Midthun was central to many key policy debates.

FDA Succession Planning Targeted In Congress As Hamburg Heads For Exit

Margaret Hamburg’s departure from commissioner post seems to be proceeding smoothly; proposals in the House 21st Century Cures discussion draft would mandate a similar process always be followed.

Hamburg, The Atypical Commissioner, Receives Atypically Fond Farewell

Margaret Hamburg’s background in public health, as opposed to academic medicine, was off-putting to some in pharma initially, but she leaves the agency in March with high drug approval numbers, initiatives to improve the OTC monograph and switch programs and increased enforcement in the supplement manufacturing arena.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS076489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel